ClinicalTrials.gg
RecruitingNCT06748001Updated Nov 12, 2026

Avapritinib Rollover Study

A Phase 4 interventional study of Avapritinib in Mastocytosis, Systemic, sponsored by Blueprint Medicines Corporation. Recruiting at 10 sites in 9 countries. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by Blueprint Medicines Corporation (part of Sanofi) · Phase 4, Interventional, and Treatment

From the registry’s dates

  • Started Nov 2024; still recruiting 1 year 11 months later.
Updated Nov 12, 2026First sites in Germany, France and Spain3 sites addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
60
Allocation
Not applicable
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies in Mastocytosis, Systemic by Sanofi — 4 open to participants now, 5 under way, 1 of them phase 3. Mastocytosis, Systemic · Sanofi.

Started
2024
the only one that year
Phase 4
Only one
of the 10
Registered
8th of 10
by date

Among the 10 studies in Mastocytosis, Systemic by Sanofi, this one is the only one that started in 2024, is the only one in phase 4, and was the 8th registered.

Mastocytosis, Systemic

56 studies on the registry are indexed under Mastocytosis, Systemic; 16 are open to participants now.

Browse Mastocytosis, Systemic studies →

Open to participants now

4 of the 10 studies in Mastocytosis, Systemic by Sanofi are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Who these studies take

Of the 14 Mastocytosis, Systemic studies recruiting now, 12 (86%) set no upper age limit and 2 (14%) stop at 75 or younger; 4 take children under 18; 1 takes healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Mastocytosis, Systemic by Sanofi, or all of them as a file.
02

Study summary

The primary objective of the rollover study is to evaluate the long-term safety of avapritinib in participants who have completed a Blueprint Medicines sponsored study (parent study) and continued to benefit from avapritinib.

03

Conditions studied

  • Mastocytosis, Systemic

Browse trials for

Keywords

  • Indolent Systemic Mastocytosis
  • ISM
  • Advanced Systemic Mastocytosis
  • AdvSM
  • Rollover study
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participated in a Blueprint Medicines sponsored avapritinib clinical study. The Sponsor reserves the right to not roll over patients who have been on drug hold for an extended time period.
  • Completed End of Trial / End of Study (EOT/EOS) visit in the parent study and demonstrated compliance with the parent study requirements.
  • Continue to clinically benefit from treatment with avapritinib.
  • Able to give written .
  • Agree to continue to use highly effective as defined in this protocol.
  • Female patients of must have negative highly sensitive serum pregnancy test within 20 days before the first dose of avapritinib. Women of nonchildbearing potential do not require this test.

Exclusion criteria

Exclusion Criteria:

  • Participant is participating in another interventional study.
  • Participant is unwilling or unable to comply with study procedures and study restrictions.
  • Participant is breastfeeding.

Other protocol-defined criteria apply.

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Avapritinib

    Participants who have participated in a Blueprint Medicines sponsored study (the parent study) and continue to benefit from avapritinib.

    Drug: Avapritinib

Interventions

  • Avapritinib will be administered in accordance with the parent study protocol.

    Also known as: BLU-285, AYVAKIT®

06

What researchers measure

Primary outcomes

  1. Incidence of Serious Adverse Events (SAEs), Adverse Events of Special Interest (AESIs), and AEs leading to Discontinuation

    Time frame: Up to approximately 4 years

07

Study locations

10 of 10 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Nov 2024 (actual). Primary completion is estimated for Dec 2027, 37 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 19, 2024
First posted
Dec 24, 2024
StartActual
Nov 28, 2024
Primary completionEst.
Dec 31, 2027
CompletionEst.
Dec 31, 2027
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
3 sites added — first sites in Germany, France and Spain
Show 3 added (1 Germany, 1 France, 1 Spain)
  • University Hospital Aachen · Aachen, Germany
  • Hôpital Pitié-Salpêtrière Charles Foix · Paris, France
  • Instituto de Estudios de Mastocitosis de Castilla la Mancha · Toledo, Spain
across 2 updates, Nov 9, 2026 – Nov 12, 2026
Show all 2 updates
  1. Nov 12, 2026
    2 sites added — first sites in France and Spain
    Show 2 added (1 France, 1 Spain)
    • Hôpital Pitié-Salpêtrière Charles Foix · Paris, France
    • Instituto de Estudios de Mastocitosis de Castilla la Mancha · Toledo, Spain
  2. Nov 9, 2026
    1 site added — first site in Germany
    Show site
    • University Hospital Aachen · Aachen, Germany
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06748001
Responsible party
Sponsor
First posted
Dec 24, 2024
Start date
Nov 28, 2024
Primary completion
Dec 31, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Nov 12, 2026

Study contacts

Blueprint Medicines
Contact
MedInfo@blueprintmedicines.com
617-714-6707

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Avapritinib

Start the discussion